Alteplase

BLOOD AND BLOOD FORMING ORGANS

Key facts

Alteplase is a drug catalogued in DrugCentral. It was first approved by the FDA in 1996. DrugCentral lists 1 molecular target, including PLG. Recorded indications include Acute myocardial infarction, Ischemic stroke and Pulmonary embolism.

• Molecular targets: PLG (1 listed in DrugCentral).
• Indications: Acute myocardial infarction, Ischemic stroke and Pulmonary embolism.
• ATC code: B01AD02 (Enzymes).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Acute myocardial infarction
• Ischemic stroke
• Pulmonary embolism

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Plasminogen	PLG	activator	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-06-18	FDA	—	GENENTECH

ATC classification

ATC code	Therapeutic hierarchy
B01AD02	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Enzymes
S01XA13	SENSORY ORGANS › OPHTHALMOLOGICALS › OTHER OPHTHALMOLOGICALS › Other ophthalmologicals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
No adverse event	7446.9
Gingival bleeding	4082.3
Haemorrhagic transformation stroke	2969.7
Cerebral haemorrhage	2784.3
Haemorrhage intracranial	2538.0
Angioedema	1594.9
Haemorrhage	1115.7
Death	1109.0
Intercepted product storage error	1071.5
Off label use	1035.7
Product storage error	923.2
Intercepted medication error	869.2

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 105857-23-6
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Alteplase used for?

DrugCentral lists the following indications for Alteplase: Acute myocardial infarction, Ischemic stroke and Pulmonary embolism.

How does Alteplase work?

Its molecular targets in DrugCentral include PLG (activator).

When was Alteplase first approved?

Alteplase was first approved by the FDA in 1996.

Sources

• DrugCentral drug card 5141 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201593 — compound record and bioactivity
• DrugBank DB00009 — drug record
• FDA UNII 1RXS4UE564 — substance identity
• DailyMed: FDA labels for Alteplase — current prescribing information (label search)
• UniProt P00747 (PLG) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.